Doripenem monohydrate is a broad-spectrum carbapenem antibiotic that is used to treat a variety of bacterial infections, including complicated intra-abdominal infections and complicated urinary tract infections. It was developed by Shionogi & Co. Ltd. The chemical name of doripenem monohydrate is (4R,5S,6S)-3-[[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate, and its molecular formula is C15H24N4O6S·H2O. The product has a formula weight of 428.46 g/mol and a CAS No of 364622-82-2.
Top Ten Keywords and Synonyms:
Health Benefits: Doripenem monohydrate has potential benefits in the treatment of bacterial infections, specifically those caused by gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae. It has been shown to be effective in treating complicated urinary tract infections and complicated intra-abdominal infections. In clinical trials, doripenem monohydrate demonstrated high rates of microbiological eradication and clinical cure.
Potential Effects: The primary effect of doripenem monohydrate is the inhibition of bacterial cell wall synthesis, which ultimately leads to bacterial cell death. It has broad-spectrum activity against gram-positive and gram-negative bacteria, including those that are resistant to other antibiotics. In clinical trials, doripenem monohydrate has demonstrated efficacy in treating complicated urinary tract infections and complicated intra-abdominal infections.
Product Mechanism: Doripenem monohydrate is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to and inhibiting penicillin-binding proteins (PBPs). This leads to the disruption of peptidoglycan cross-linking and ultimately bacterial cell death. Doripenem monohydrate also has broad-spectrum activity against gram-positive and gram-negative bacteria, including those that are resistant to other antibiotics.
Safety: In clinical trials, doripenem monohydrate has been generally well-tolerated by patients, with no reported serious adverse events. However, like all drugs, there are potential risks associated with its use. Patients with a history of hypersensitivity to beta-lactam antibiotics, as well as those with renal impairment, should consult with their healthcare provider before using doripenem monohydrate.
Side Effects: The most common side effects reported in clinical trials were diarrhea, nausea, and headache. These side effects were generally mild to moderate in severity and resolved without intervention. Other less common side effects included allergic reactions, rash, and liver enzyme abnormalities.
Dosing Information: The recommended dose of doripenem monohydrate varies depending on the type of infection being treated and the patient's age and weight. In clinical trials for complicated urinary tract infections and complicated intra-abdominal infections, the typical dose was 500 mg every eight hours, administered intravenously over one hour. Dosing adjustments may be necessary in patients with renal impairment. It is important to follow your healthcare provider's instructions regarding dosing and administration of doripenem monohydrate.
Conclusion: Doripenem monohydrate is a promising antibiotic for the treatment of bacterial infections, specifically those caused by gram-negative bacteria. Its inhibition of bacterial cell wall synthesis leads to bacterial cell death, making it effective against a broad range of bacterial strains. While doripenem monohydrate has been generally well-tolerated in clinical trials, patients should consult with their healthcare provider before using this medication. With further research, doripenem monohydrate may prove to be a valuable addition to the treatment options available for bacterial infections
